wePool Inc.

wePool is revolutionizing infectious disease and diagnostic assay testing efficiency with Artificial Intelligence. Our decision support platform designed for COVID-19 can deliver test kit savings of up to 70%, enabling up to a 300% increase in sample analysis capacity. With wePool AI, we can scale COVID-19 testing and help labs meet the otherwise-overwhelming demand as the pandemic spreads. Powered by AI, wePool's platform predicts an individual sample’s likelihood for testing positive for COVID-19, and segments test populations into distinct groups, or “pools,” to enable fast and efficient testing. Leveraging pooled testing which has demonstrated efficacy historically for disease outbreak management, wePool’s AI uses sociodemographic and healthcare data as inputs to intelligently arrange pools of predictably negative samples and separate predictably positive samples. The platform is designed to seamlessly integrate with lab workflows and to equip clinicians with the real-time metrics to evaluate performance and efficiency. The technology can be applied for PCR, Antibody, Antigen, Next Generation Sequencing, and other infectious disease testing assays (e.g. Influenza A/B, Malaria, HIV, HPV, and others). With success demonstrated through the COVID-19 pandemic, wePool aspires to establish their AI-powered decision support platforms as a valuable standard tool for large scale or mass testing, specifically in the context of epidemic and pandemic preparedness scenarios.